Company Encyclopedia
View More
name
Co-Diagnostic
CODX.US
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
1.380 T
CODX.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking135/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-62.12%E
    • Profit Margin-6336.27%E
    • Gross Margin81.92%A
  • Growth ScoreE
    • Revenue YoY-93.06%E
    • Net Profit YoY22.05%B
    • Total Assets YoY-38.19%E
    • Net Assets YoY-37.56%E
  • Cash ScoreE
    • Cash Flow Margin-1.58%D
    • OCF YoY-93.06%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio10.98%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Co-Diagnostics Unveils Portable Cloud-Connected PCR Platform at Boston Conference

    Co-Diagnostics Inc. unveiled its portable, cloud-connected PCR platform at the Point-of-Care Testing 2025 Conference in Boston. The platform features a smartphone interface and AI integration to reduce user error and improve real-time testing. This marks a significant step towards portable PCR diagnostics for point-of-care applications.

    Reuters·
    US
    CODX
    -2.01%
    Reuters·
    US
    CODX
    -2.01%

    Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India | CODX Stock News

    Co-Diagnostics, Inc. announced that its joint venture, CoSara, will participate in VIROCON 2025 in Pune, India. CoSara is advancing Phase II preclinical studies for Co-Dx PCR MTB and HPV tests, supporting their progression to clinical performance testing. The event, organized by ICMR-NIV, aims to foster scientific collaborations to address viral epidemics. Co-Diagnostics' technologies are under regulatory review and not yet available for sale.

    StockTitan·
    US
    CODX
    -2.01%
    StockTitan·
    US
    CODX
    -2.01%

    Co-Diagnostics Inc. held shareholder meeting on reverse stock split proposal

    Co-Diagnostics Inc. held a special shareholder meeting on December 5, 2025, where shareholders approved a reverse stock split proposal. The Board will determine the split ratio within twelve months. This information was published via EDGAR by Co-Diagnostics Inc.

    Reuters·
    US
    CODX
    -2.01%
    Reuters·
    US
    CODX
    -2.01%

    CFO Brown Surrenders 40,723 Of Co-Diagnostics Inc [CODX]

    CFO Brian Lee Brown of Co-Diagnostics Inc surrendered 40,723 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on November 24, 2025. His ending holdings are 599,355 shares directly.

    Reuters·
    US
    CODX
    -2.01%
    Reuters·
    US
    CODX
    -2.01%

    Chmn Egan Surrenders 49,575 Of Co-Diagnostics Inc [CODX]

    Egan Dwight H, Chairman of Co-Diagnostics Inc, surrendered 49,575 shares back to the company to cover option exercise costs and tax liabilities. This transaction was disclosed in a Form 4 filed with the SEC on November 24, 2025. His ending holdings are 748,252 shares directly.

    Reuters·
    US
    CODX
    -2.01%
    Reuters·
    US
    CODX
    -2.01%
    © 2025 Longbridge｜Disclaimer